Review
Copyright ©The Author(s) 2017.
World J Cardiol. Jul 26, 2017; 9(7): 562-573
Published online Jul 26, 2017. doi: 10.4330/wjc.v9.i7.562
Table 1 Studies demonstrating associations between rheumatoid arthritis and QT parameters, inflammation and mortality
Ref.DesignRA patientsControlsImpact of RA and QT dispersion (QTd) and QTcAssociation between QT parameter, and disease activity/duration (1), arrhythmia (2), autonomic dysfunction (3), mortality (4)
[54]Cross-sectional4242↑ QTd variables (QTd, QTcD, JTD, JTcD) vs controls No difference in QTc vs controls(1) ESR, CRP (2) Complex premature ventricular beats
[55]Cross-sectional4048↑ QTd variables (QTd, QTcD) vs controls(1) Disease duration
[56]Cross-sectional4040↑ QTd vs controls(1) Extra-articular manifestations, erosive disease
[57]Cross-sectional5829↑ QT vs controls(1) Secondary Sjörgen’s syndrome
[58]Cross-sectional100100↑ QTd vs controls(1) Disease duration, DAS28, ESR, number of joints involved
[59]Cross-sectional2521 controls 76 with spondylarthopathy↑ QTc vs controls and those with spondyloarthopathies Infliximab therapy duration inversely correlated to QTc (P < 0.01)(1) CRP (3) ↑ QTC associated with ↑ HR, autonomic dysfunction, particularly sympathetic dysfunction as assessed by spectral parameters of heart rate variability
[60]Prospective cohort357_↑ QTc 10% males (QTc ≥ 450 ms) and 5.6% of females (QTc ≥ 460 ms)(1) CRP (4) Doubled risk of all-cause mortality per 50 ms increase in QTc, (lost after adjustment for CRP) HR = 2.17 (95%CI: 1.21-3.90)
[61]Retrospective cohort417422↑ % of RA patients with QTc prolongation (> 450 ms males, > 460 ms females) vs controls 20 yr after disease onset (48% vs 38%, P = 0.004)(1) ESR (4) Any cause QTc prolongation was associated with ↑ all-cause mortality HR = 2.99 (95%CI: 1.93-4.65)
[62]Prospective cohort17_↑ QTc (> 440 ms) in 76% of patients Toclizumab associated with 47% ↓ in No. patients with QTc prolongation (P = 0.006)(1) CRP and TNF-α
[70]Cross-sectional117-(1) CRP, TNF-α, IL-1β and IL 10 ( QTc BAZ) (1) IL-1β and IL 10, trend towards TNF-α (QTc FHS)